Wall Street brokerages forecast that vTv Therapeutics Inc (NASDAQ:VTVT) will report sales of $1.69 million for the current quarter, according to Zacks. Two analysts have provided estimates for vTv Therapeutics’ earnings, with estimates ranging from $880,000.00 to $2.50 million. vTv Therapeutics reported sales of $3.38 million during the same quarter last year, which indicates a negative year-over-year growth rate of 50%. The firm is expected to report its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that vTv Therapeutics will report full-year sales of $6.16 million for the current year, with estimates ranging from $4.62 million to $7.70 million. For the next financial year, analysts anticipate that the company will post sales of $6.38 million, with estimates ranging from $2.75 million to $10.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.63 million.

Several research firms have commented on VTVT. Zacks Investment Research cut vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of vTv Therapeutics in a research note on Friday. ValuEngine cut vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 3rd. Finally, Northland Securities restated a “buy” rating and issued a $8.00 target price on shares of vTv Therapeutics in a research note on Thursday, August 1st.

NASDAQ VTVT traded up $0.05 during trading on Friday, hitting $1.34. The stock had a trading volume of 2,536 shares, compared to its average volume of 197,479. The company has a market capitalization of $70.91 million, a PE ratio of -1.93 and a beta of -3.71. The company’s 50-day moving average price is $1.38 and its two-hundred day moving average price is $1.70. vTv Therapeutics has a 12 month low of $0.68 and a 12 month high of $6.09.

In related news, major shareholder Ronald O. Perelman purchased 150,000 shares of the stock in a transaction on Monday, August 19th. The shares were purchased at an average price of $1.31 per share, with a total value of $196,500.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ronald O. Perelman purchased 1,212,121 shares of the stock in a transaction on Tuesday, July 9th. The shares were bought at an average cost of $1.65 per share, for a total transaction of $1,999,999.65. The disclosure for this purchase can be found here. Insiders have acquired a total of 3,786,363 shares of company stock worth $6,196,499 in the last ninety days. Insiders own 1.70% of the company’s stock.

A hedge fund recently raised its stake in vTv Therapeutics stock. BlackRock Inc. increased its holdings in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 65,031 shares of the biotechnology company’s stock after acquiring an additional 13,305 shares during the quarter. BlackRock Inc. owned about 0.12% of vTv Therapeutics worth $93,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 3.71% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Story: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.